The APP Knockout Jurkat Polyclonal Cells product comprises a population of CRISPR/Cas9-edited Jurkat cells with targeted disruption of the APP gene, designed to create a loss-of-function model for studying amyloid precursor protein biology. As a polyclonal knockout pool, this product contains a heterogeneous collection of Jurkat cells harboring diverse mutations at the APP locus, collectively abolishing functional expression of the encoded protein. This format is particularly suited for applications that do not require clonal homogeneity, such as pooled screening or phenotypic assays where bulk abrogation of gene activity is sufficient. The CRISPR/Cas9-mediated gene disruption was achieved without selection of a specific editing pattern, ensuring a representative knockout population for downstream analyses.
The parental Jurkat cell line is an immortalized human T lymphocyte line originally established from an acute T cell leukemia patient, serving as a widely used model for T cell biology and adaptive immunity. Jurkat cells exhibit key features of mature T cells, including expression of the T cell receptor complex and responsiveness to various immunomodulatory stimuli, and they retain the capacity to mediate cellular immune functions. This cell line provides a robust and experimentally tractable background for investigating gene function in a hematopoietic context, particularly for signaling pathways relevant to lymphocyte activation, adhesion, and apoptosis.
Amyloid precursor protein (APP) is a type I transmembrane protein with multifaceted roles in neuronal development, cell adhesion, signal transduction, and synaptic plasticity. Beyond its well-characterized processing by BACE1 and the gamma-secretase complex (composed of PSEN1, nicastrin, APH1, and PEN2) into amyloid-beta (A??) peptides, APP undergoes sequential cleavage by ADAM10 to release the soluble ectodomain, leaving behind a C-terminal fragment that is further processed by gamma-secretase to generate the APP intracellular domain (AICD). AICD translocates to the nucleus, where it interacts with adaptor proteins such as Fe65 and X11/Mint to form transcriptionally active complexes that regulate genes like neprilysin, GSK3B, and p53. APP also engages in extracellular interactions with integrins and heparan sulfate proteoglycans (HSPGs), and it can heterodimerize with family members APLP1 and APLP2, modulating cell-matrix adhesion and downstream Wnt and Notch pathway components.
The ablation of APP in Jurkat cells eliminates the production of A?? peptides and AICD-mediated transcriptional signaling, disrupting critical interactions with adaptor proteins Fe65 and Dab1 that are implicated in both neuronal and immune cell functions. This disruption may impair gamma-secretase-dependent Notch signaling and alter Wnt pathway cross-talk, leading to downstream effects on cell adhesion, apoptotic responses, and potentially T cell receptor-mediated activation. Since APP is expressed in hematopoietic cells and its processing machinery is active in T lymphocytes, Jurkat APP knockout cells serve as a relevant non-neuronal model to dissect cell-type-specific roles of APP in adaptive immunity, independent of neuronal context or the presence of other APP family members.
This knockout model enables a broad range of research applications, including the study of APP-dependent signal transduction in T lymphocytes, investigation of gamma-secretase substrate selectivity using pharmacological inhibitors, and screening for small molecules that modulate APP processing. The polyclonal knockout population is well-suited for functional assays such as Western blotting to confirm loss of APP and its cleavage products, flow cytometry for cell surface APP expression, and co-immunoprecipitation to assess Fe65 or BACE1 interaction dynamics. Additional applications include dual-luciferase reporter assays for AICD transactivation activity and Annexin V-based apoptosis assays to evaluate the impact of APP loss on programmed cell death. For further technical inquiries regarding this product, please contact Ascent Research.
